Treatment of Refractory (Acute or Chronic) Graft-Versus-Host Disease by the Infusion of Expanded in-Vitro Allogenic Mesenchymal Stem Cell

Inclusion Criteria: * Patients with hematological malignancies who had been undergone an allogenic hematopoietic stem cell transplant and diagnosed with GVHD refractory to a usual treatment. * Adequate cardiac function with no evidence of uncontrolled high blood pressure,congestive heart failure, angina pectoris, acute myocardial infarction within 6 months prior to the process. * Adequate pulmonary function with no evidence of chronic obstructive or severe restrictive pulmonary disease. * Patients with ages between 18 and 65 years. * Signature of informed consent form is required to be done by patient and donor. Exclusion Criteria: * Patients whose hematopathology has not been controlled by the transplant or is in progress. * Patients with bacterial, viral or fungal infection not being controlled with the adequate treatment. * Patients with an inadequate cardiac or pulmonary function. * Patients who, in the investigator´s point of view, are not in situation to tolerate the treatment. * Patients who do not have the required donor (HLA-identical sibling donor and not HLA-identical sibling donor). * Pregnant females or childbearing potential who are not on adequate contraceptive measures. * Patients \<18 or \>65 years. * Patients who do not sign the informed consent.